Distribution of human umbilical cord blood-derived mesenchymal stem cells in the Alzheimer's disease transgenic mouse after a single intravenous injection

NeuroReport

Volumn 27, Issue 4, 2016, Pages 235-241

  Park, Sang Eon ^a,b,c   Lee, Na Kyung ^a,b,c   Lee, Jeongmin ^a,b,c   Hwang, Jung Won ^a,b,c   Choi, Soo Jin ^d   Hwang, Hyeri ^e   Hyung, Brian ^f   Chang, Jong Wook ^a   Na, Duk L ^a,b,c  

^a Sungkyunkwan University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

^d MEDIPOST Co Ltd   (South Korea)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer disease transgenic mouse; Blood brain barrier; Human umbilical cord blood derived mesenchymal stem cell; Intravenous

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; TRANSCRIPTION FACTOR SOX2; AMYLOID PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; SOX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SOX;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; HEART; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD; WESTERN BLOTTING; ANIMAL; CAPILLARY PERMEABILITY; CARDIAC MUSCLE; DISEASE MODEL; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSGENIC MOUSE; XENOGRAFT;

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, TRANSGENIC; MYOCARDIUM; NEPRILYSIN; PRESENILIN-1; SOXB1 TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84957935061     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000526     Document Type: Article

References (32)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
2. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010;7:656-664.
3. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003;24:1063-1070.
4. Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science 2010;327:1309.
5. Jia Q, Deng Y, Qing H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int 2014;2014:837157.
6. Zheng H, Fridkin M, Youdim M. From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel) 2014;7:113-135.
7. Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2007;2:347-359.
8. Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med 2010;77:32-42.
9. Kim DH, Lee D, Chang EH, Kim JH, Hwang JW, Kim JY, et al. GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered via CSF promote hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model. Stem Cells Dev 2015;24:2378-2390.
10. Kim JY, Kim DH, Kim DS, Kim JH, Jeong SY, Jeon HB, et al. Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces amyloid-beta42 neurotoxicity in vitro. FEBS Lett 2010;584:3601-3608.
11. Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ 2012;19:680-691.
12. Lee HJ, Lee JK, Lee H, Shin JW, Carter JE, Sakamoto T, et al. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci Lett 2010;481:30-35.
13. Tanna T, Sachan V. Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Curr Stem Cell Res Ther 2014;9:513-521.
14. Kim JY, Kim DH, Kim JH, Yang YS, Oh W, Lee EH, Chang JW. Umbilical cord blood mesenchymal stem cells protect amyloid-β42 neurotoxicity via paracrine. World J Stem Cells 2012;4:110-116.
15. Yun HM, Kim HS, Park KR, Shin JM, Kang AR, il Lee K, et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1-42-infused mouse model of Alzheimer's disease. Cell Death Dis 2013;4:e958.
16. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003;6:252-273.
17. Liu L, Eckert MA, Riazifar H, Kang DK, Agalliu D, Zhao W. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int 2013;2013:435093.
18. Anbari F, Khalili MA, Bahrami AR, Khoradmehr A, Sadeghian F, Fesahat F, Nabi A. Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury. Neural Regen Res 2014;9:919-923.
19. Gutiérrez-Fernández M, Rodríguez-Frutos B, Ramos-Cejudo J, Teresa Vallejo-Cremades M, Fuentes B, Cerdán S, Díez-Tejedor E. Effects of intravenous administration of allogenic bone marrow- and adipose tissuederived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther 2013;4:11.
20. Quertainmont R, Cantinieaux D, Botman O, Sid S, Schoenen J, Franzen R. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One 2012;7:e39500.
21. Kim S, Chang KA, Ja Kim, Park HG, Ra JC, Kim HS, Suh YH. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer's disease mice. PLoS One 2012;7:e45757.
22. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004;313:856-862.
23. Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. J Vis Exp 2013;73:e50062.
24. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 2007;16:285-299.
25. Marques F, Sousa JC, Sousa N, Palha JA. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 2013;8:38.
26. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013;33:1500-1513.
27. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009;1788:842-857.
28. Osterstock G, Escobar P, Mitutsova V, Gouty-Colomer LA, Fontanaud P, Molino F, et al. Ghrelin stimulation of growth hormone-releasing hormone neurons is direct in the arcuate nucleus. PLoS One 2010;5:e9159.
29. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
30. Zhao W, Li JJ, Cao DY, Li X, Zhang LY, He Y, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 2012;18:1048-1058.
31. Kurtz A. Mesenchymal stem cell delivery routes and fate. Int J Stem Cells 2008;1:1-7.
32. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.